Skip to content

Cardinal Health CAH Cost of product sold — Goodwill

Other segment segments

Pharmaceutical and Specialty Solutions
$9.67B+25.0%
Other Segments
$1.75B+49.3%

Similar metrics at other companies

SPX Technologies logo
SPXCCost of products sold — Goodwill
$366.2M+1.4%
Teradata logo
TDCProduct Sales — Goodwill
$392M+1.3%
Columbus McKinnon Corporation logo
CMCORest of Products — Goodwill
$320.08M+7.5%
Opko Health logo
OPKPharmaceutical — Goodwill
$318.83M
SPX Technologies logo
SPXCCost of products sold — Goodwill, Gross
$541.7M+1.2%
Cadre Holdings logo
CDREProducts — Goodwill
$228.61M+56.6%

Other financials

Income statement

See full
Revenue$60.9B+11.0%
Gross profit$2.5B+17.7%
Operating income$509.0M-30.3%
Net income$399.0M-21.1%
EPS (diluted)$1.69-19.5%

Balance sheet

See full
Cash & equivalents$3.9B+18.4%
Total debt$8.9B+16.1%
Total equity-$2.8B+3.9%
Total assets$56.7B+13.7%

Cash flow

See full
Operating cash flow$1.8B-37.6%
CapEx$146.0M+15.9%
Free cash flow$1.7B-40.0%

Valuation

See full
Market cap$54.98B+41.0%
Enterprise value$59.96B+38.3%
P/E35.4×+10.3×
P/S0.2×0.0×

Profitability

See full
Gross margin3.8%+0.2pp
Operating margin0.9%-0.1pp
Net margin0.6%-0.1pp
FCF margin1.7%+0.6pp

Returns & leverage

See full
Return on equity37.4%
Debt / equity4.1×
Current ratio0.9×0.0×

Where this comes from

Reported directly by Cardinal Health in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Cardinal Health’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cardinal Health's cost of product sold — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cardinal Health's cost of product sold — goodwill?
Cardinal Health (CAH) reported cost of product sold — goodwill of $0 in Q1 2026.
What does cost of product sold — goodwill mean?
This metric represents the portion of goodwill allocated to the cost of product sold segment. It reflects the intangible value associated with past acquisitions that is attributed to the operational performance of the pharmaceutical distribution business.